Showing 1171-1180 of 1211 results for "".
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- Bausch + Lomb Acquires Eton Pharmaceuticals’ EM-100 Investigational OTC Eye Drop For Allergic Conjunctivitishttps://modernod.com/news/bausch-health-acquires-eton-pharmaceuticals-em-100-investigational-eye-drop-for-the-treatment-of-itchy-eyes-associated-with-allergies/2476282/Bausch Health Companies’ subsidiary Bausch + Lomb has acquired the US rights to Eton Pharmaceuticals’ investigational eye drop EM-100. If approved, the eye drop will be the first over-the-counter preservative-free formulation eye drop for the treatment of ocular itching associated wit
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Beaver-Visitec International to Acquire PhysIOL Grouphttps://modernod.com/news/tpg-capital-backs-bvi-to-acquire-physiol-group-sa/2476246/Beaver-Visitec International (BVI) announced it has signed a definitive agreement to acquire PhysIOL Group, a Belgium-based ophthalmic company specializing in the research, development, and manufacture of IOLs, from TA Associates. Financial terms of the transaction were not disclosed.
- For 2019, ADA and ACC Align Their Diabetes Recommendationshttps://modernod.com/news/for-2019-ada-and-acc-align-their-diabetes-recommendations/2476250/For the first time in its annual diabetes management guidelines, the American Diabetes Association (ADA) has aligned its recommendations with those of the American College of Cardiology (ACC) for cardiovascular risk reduction in people with type 2 diabetes, according to a report in Medscape.
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Takeda Gains Clearance from European Commission for Shire Purchasehttps://modernod.com/news/takeda-gains-clearance-from-european-commission-for-shire-purchase/2479653/Takeda announced Tuesday that it received clearance from the European Commission for its proposed $62-billion acquisition of Shire, with the condition that Takeda sells its experimental anti-integrin agent SHP647 and certain associated rights. Takeda said it expects SHP647 “to attract inter
- Prevent Blindness Elects Three New Members to National Board of Directorshttps://modernod.com/news/prevent-blindness-elects-three-new-members-to-national-board-of-directors-2/2479700/Prevent Blindness has announced that Paul Delatore, Global Head, Market Access at Alcon; Jim McGrann, Chairman & CEO of Healthy Eyes Advantage; and Rajeev S. Ramchandran, MD, Associate Professor of Ophthalmology in the University of Rochester Medical School’s Department of Ophthalmology, have
- Placing a Bypass Stent During Cataract Surgery Cuts Need for Glaucoma Eyedropshttps://modernod.com/news/placing-a-bypass-stent-during-cataract-surgery-cuts-need-for-glaucoma-eyedrops/2479808/Implantation of the iStent Trabecular Micro-Bypass in conjunction with cataract surgery is associated with reduced need for glaucoma eyedrops, according to a new study. “Our results suggest that for certain groups of patients, such as those with glaucoma who are taking one or more gl